June 2019 - Volume 3 - Issue - Contributor Index

Author:
C, L. K
Author:
C, M.-R. M
Author:
C, S. B. M
Author:
Caballero, D.

TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE 2 STUDY: S869

Witzig, T.; Sokol, L.; Kim, W. S.; More

HemaSphere. 3:389, June 2019.

TANDEM AUTOLOGOUS-REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGH-RISK RELAPSED HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY OF THE LWP-EBMT: S1622

Bento, L.; Boumendil, A.; Fine, H.; More

HemaSphere. 3:749-750, June 2019.

Author:
Caballero, G.

CURRENT DOSE RECOMMENDATIONS FOR PONATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS CAN DIMINISH ADVERSE EVENTS WHILE MAINTAINING EFFICACY: PS1186

Garcia-Gutierrez, V.; Hernandez-Boluda, J. C.; Moiraghi, B.; More

HemaSphere. 3:540-541, June 2019.

ASSESSMENT OF THE BURDEN OF DISEASE IN TERMS OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR ASCT IN SPAIN: INTERIM ANALYSIS OF QOLMMBUS STUDY: PS1391

de la Rubia, J.; Domingo, A.; Delgado, O.; More

HemaSphere. 3:638, June 2019.

ROLE OF SOMATIC MUTATIONS IN PATIENTS WITH HIGH-RISK MYELODISPLASTIC SYNDROMES TREATED WITH INTENSIVE CHEMOTHERAPY: PB2080

Caballero, J. C.; Sánchez, Hernández J. M.; Abáigar, M.; More

HemaSphere. 3:937-938, June 2019.

INFECTIOUS COMPLICATIONS FOLLOWING ARI-0001 CELL (A3B1:CD8:4-1BB:CD3Z CART19) TREATMENT IN ADULT AND PEDIATRIC PATIENTS WITH CD19+ RELAPSED / REFRACTORY MALIGNANCIES: PS1214

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Cardozo, C.; More

HemaSphere. 3:553-554, June 2019.

FRACTIONATED DOSING OF ARI-0001 CELLS (A3B1:CD8:4-1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES: S1636

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Caballero-Baños, M.; More

HemaSphere. 3:756, June 2019.

SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE: PS943

Dourthe, M. E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3:425, June 2019.

Author:
cabarkapa, V.
Author:
Cabero, A.

REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE: PF757

Espigado, I.; Rodriguez, N.; Labrador, G.; More

HemaSphere. 3:332-333, June 2019.

EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA. RETROSPECTIVE ANALYSIS IN OUR CENTER: PB2350

Romero, Gonzalez Y.; Mora, J.; Cortes, M. A.; More

HemaSphere. 3:1047, June 2019.

Author:
Cabiati, B.

GMP MANUFACTURING OF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) CYTOKINE INDUCED KILLER (CIK) CELLS WITH SLEEPING BEAUTY (SB) TRANSPOSON FOR ADOPTIVE IMMUNOTHERAPY: PF436

Magnani, C. F.; Gaipa, G.; Belotti, D.; More

HemaSphere. 3:171, June 2019.

Author:
Cabral, R.
Author:
Cabras, A.

VERY LATE REALAPSES (VLR) ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY±RADIOTHERAPY (CT±RT) IN HODGKIN LYMPHOMA (HL): A JOIN STUDY ON TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME: PF472

Vassilakopoulos, T.; Liaskas, A.; Rizzuto, G.; More

HemaSphere. 3:187-188, June 2019.

Author:
Cabras, M. G.

PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL): S1597

Balzarotti, M.; Spina, M.; Monagheddu, C.; More

HemaSphere. 3:735, June 2019.

Author:
Cabrera, A.

SURVIVAL ANALYSIS OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH INTENSIVE CHEMOTHERAPY: RESULTS OF A MEXICAN NATIONAL AML REGISTRY.: PB1739

Demichelis, R.; Zapata, N.; Leyto, F.; More

HemaSphere. 3:800, June 2019.

OVERAL SURVIVAL OF MEXICAN NATIONAL REGISTRY OF ACUTE PROMYEOLOCYTIC LEUKEMIA, AN ANALYSIS OF 324 CASES: PB1773

Zapata, N.; Montaño, E.; Ramos, C.; More

HemaSphere. 3:814, June 2019.

SAFETY AND EFFECTIVENESS OF CHLORAMBUCIL-OBINUTUZUMAB IN THE FRONT LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-LIFE DATA FROM ANDALUSIAN LYMPHOID NEOPLASM GROUP (GRANEL): PB1898

Puerta, Puerta J.M.; Palanco, Martín V.; Badiola, J.; More

HemaSphere. 3:865, June 2019.

Author:
Cabrera, W.
Author:
Cacciola, E.
Author:
Cacciola, R.

IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS: PS1468

Barbui, T.; Ghirardi, A.; Masciulli, A.; More

HemaSphere. 3:667-668, June 2019.

Author:
Caceres, J. F.
Author:
Cachat, F.
Author:
Cacheux, V.

OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL: S103

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3:3, June 2019.

FLOW CYTOMETRY CHALLENGE FOR MEASURABLE RESIDUAL DISEASE MONITORING IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS RECEIVING TARGETED IMMUNOTHERAPY: PB1660

Bermejo, Yeguas A.; García-Sancho, Martín A.; Morón, Puig N.; More

HemaSphere. 3:768, June 2019.

ROLE OF SOMATIC MUTATIONS IN PATIENTS WITH HIGH-RISK MYELODISPLASTIC SYNDROMES TREATED WITH INTENSIVE CHEMOTHERAPY: PB2080

Caballero, J. C.; Sánchez, Hernández J. M.; Abáigar, M.; More

HemaSphere. 3:937-938, June 2019.

Author:
Cadievski, L.
Author:
Caers, J.
Author:
Cafforio, L.

PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH “BORDERLINE” PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: PF365

Raponi, S.; Ilari, C.; Della Starza, I.; More

HemaSphere. 3:134-135, June 2019.

Author:
Caforio, M.
Author:
Cafro, A.
Author:
Cafro, A. M.

TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS‘ CHARACTERISTICS IN MULTIPLE MYELOMA: PF579

Muccio, V. E.; Gilestro, M.; Saraci, E.; More

HemaSphere. 3:241-242, June 2019.

Author:
Cagnetta, A.
Author:
Cahn, J.-Y.

DE NOVO ADULT ACUTE MYELOID LEUKEMIA PATIENTS DISPLAY AT DIAGNOSIS FUNCTIONAL DEREGULATION OF REDOX BALANCE CORRELATED WITH MOLECULAR SUBTYPES AND OVERALL SURVIVAL: PS993

Mondet, J.; Lo Presti, C.; Garrel, C.; More

HemaSphere. 3:446-447, June 2019.

Author:
cai, J.
Author:
Cai, X.

INCIDENCE, CLINICAL FEATURES, RISK FACTORS AND OUTCOMES OF REFRACTORY ACQUIRED IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: A CHINESE MULTI-CENTER EXPERIENCE: PF805

Gui, R.-Y.; Zhang, G.-C.; Wang, C.-C.; More

HemaSphere. 3:355, June 2019.

INCIDENCE, RISK FACTORS AND OUTCOMES OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION: PB2361

Cai, X.; Wu, J.; Gui, R.-Y.; More

HemaSphere. 3:1052, June 2019.

Author:
Cai, Y.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION CAN ABROGATE INCREASING RISK OF RELAPSE FROM PERSISTENT MUTATIONS MEASURED BY TARGETED SEQUENCING AT REMISSION IN NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA: S1613

Kim, T.; Ahn, J.-S.; Jung, S.-H.; More

HemaSphere. 3:743-744, June 2019.

SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE: PS943

Dourthe, M. E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3:425, June 2019.

Author:
Caillon, H.

PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS: S145

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3:24-25, June 2019.

Author:
Caillot, D.

PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS: S145

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3:24-25, June 2019.

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA: PF592

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3:248-249, June 2019.

BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PF594

Rosiñol, L.; Hebraud, B.; Oriol, A.; More

HemaSphere. 3:249-250, June 2019.

STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY: PF598

Hulin, C.; Moreau, P.; Attal, M.; More

HemaSphere. 3:252, June 2019.

Author:
Cain, L.

HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE-MM3: PF626

Schjesvold, F.; Goldschmidt, H.; Maisnar, V.; More

HemaSphere. 3:266-267, June 2019.

Author:
Caini, M.
Author:
Cairns, D.

EFFICACY OF QUADRUPLET KCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE) INDUCTION FOR NEWLY DIAGNOSED MYELOMA PATIENTS: ANALYSIS OF THE MYELOMA XI STUDY BY MOLECULAR RISK: S873

Pawlyn, C.; Kaiser, M.; Davies, F.; More

HemaSphere. 3:391, June 2019.

Author:
Cairo, S.
Author:
Cairoli, R.

PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS: PF529

Crucitti, L.; Rusconi, C.; Re, A.; More

HemaSphere. 3:217, June 2019.

Author:
Caja, T.
Author:
Cakar, Kizil M.
Author:
Cake, S.

SAFETY ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA: PS1068

Verner, E.; Johnston, A.; Pati, N.; More

HemaSphere. 3:483-484, June 2019.

Author:
Çakir, M.
Author:
calabrese, C.
Author:
Calabresi, L.
Author:
Calabretto, G.

TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL): PS1145

Pagano, M. A.; Tibaldi, E.; Brunati, A. M.; More

HemaSphere. 3:518-519, June 2019.

Author:
Calabrò, M.
Author:
Calafiore, V.

FEASIBILITY, TOLERABILITY AND EFFICACY OF CARFILZOMIB, LENALIDOMIDE AND DESAMETHASONE(KRD) IN RELAPSED REFRACTORY MYELOMA PATIENTS: A REAL-LIFE SURVEY OF THE SICILIAN MYELOMA NETWORK: PB2123

Conticello, C.; Martino, E.; Calafiore, V.; More

HemaSphere. 3:956, June 2019.

Author:
Calaminici, M.
Author:
Calasanz, M. J.

COMPARISON OF FOUR NGS PANELS AND ANALYSIS OF THEIR CLINICAL UTILITY IN MYELOID HEMATOLOGICAL MALIGNANCIES OF THE MYELOID LINAGE: PF220

Aguilera-Diaz, A.; Vazquez, I.; Ariceta, B.; More

HemaSphere. 3:62, June 2019.

TUMOR NGS-PANEL UTILITY IN THE IDENTIFICATION OF GERMLINE VARIANTS IN MYELOID MALIGNANCIES: PF238

Palomino-Echeverria, S.; Vazquez, I.; Alfonso-Pierola, A.; More

HemaSphere. 3:71-72, June 2019.

CHROMATIN ACTIVATION AS A UNIFYING PRINCIPLE UNDERLYING PATHOGENIC MECHANISMS IN MULTIPLE MYELOMA: PF567

Ordoñez, R.; Kulis, M.; Russiñol, N.; More

HemaSphere. 3:236, June 2019.

COMPREHENSIVE ANALYSIS OF THE COMPLEXITY AND HETEROGENEITY OF THE LNCRNAS TRANSCRIPTOME IN MULTIPLE MYELOMA: PF583

Carrasco-Leon, A.; Ezponda, T.; Meydan, C.; More

HemaSphere. 3:243, June 2019.

HEAVY&LIGHT CHAIN MONITORING IN HIGH RISK SMOLDERING MULTIPLE MYELOMA PATIENTS INCLUDED IN THE GEM-CESAR TRIAL: COMPARISON WITH CONVENTIONAL AND MINIMAL RESIDUAL DISEASE IMWG RESPONSE ASSESSMENT: PF609

Puig, N.; Contreras, T.; Paiva, B.; More

HemaSphere. 3:258, June 2019.

A NEW NEXT-GENERATION SEQUENCING STRATEGY FOR THE SIMULTANEOUS DETECTION OF GENE MUTATIONS AND COPY NUMBER VARIATIONS IN MYELOID MALIGNANCIES: PS1008

Prieto-Conde, M. I.; Vázquez, I.; Fernández-Mercado, M.; More

HemaSphere. 3:453, June 2019.

INDIVIDUALIZED FOLLOW-UP IN ADULT ACUTE MYELOID LEUKEMIA USING NGS: PS1009

Iturri, Blasco Z.; Vazquez, I.; Ariceta, B.; More

HemaSphere. 3:453-454, June 2019.

LOW-COVERAGE WHOLE GENOME SEQUENCING OUTPERFORMS FISH IN COPY NUMBER VARIATION DETECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA: PS1146

Ariceta, B.; Aguilera-Díaz, A.; Vázquez, I.; More

HemaSphere. 3:519, June 2019.

CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL: PS1351

Ubieto, Jiménez A.; Martinez-Lopez, J.; Paiva, B.; More

HemaSphere. 3:617, June 2019.

Author:
Calasanz, M.-J.

CURATIVE STRATEGY (GEM-CESAR) FOR HIGH-RISK SMOLDERING MYELOMA: CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) AS INDUCTION FOLLOWED BY HDT-ASCT, CONSOLIDATION WITH KRD AND MAINTENANCE WITH RD: S871

Mateos, M.-V.; Martínez-López, J.; Rodríguez-Otero, P.; More

HemaSphere. 3:390, June 2019.

Show: